The Value of Juvenile Animal Studies: A Pediatric Clinical Perspective

被引:2
|
作者
Rose, Klaus [1 ]
机构
[1] Klausrose Consulting, CH-4052 Basel, Switzerland
关键词
pediatric drug development; better medicines for children; clinical meaningfulness of juvenile animal studies; DRUG; PHARMACOLOGY;
D O I
10.1002/bdrb.20306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the emphasis of US American and European legislators on consideration of children in the drug development process regulatory authorities ask increasingly for additional non-clinical data to elucidate the safety of a given drug in development in future pediatric use. Juvenile animal studies are increasingly requested. These requests should never be tick box requests. Companies, academic toxicologists, clinicians, and regulatory authorities need a dialogue to differentiate between the perceived need to do "something" and the request for studies that have clinically meaningful results. Birth Defects Res (Part B) 92:252-253, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:252 / 253
页数:2
相关论文
共 50 条
  • [1] The Value of Juvenile Animal Studies: A Japanese Industry Perspective
    Shimomura, Kazuhiro
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2011, 92 (04) : 266 - 268
  • [2] Juvenile Animal Studies and Pediatric Drug Development: A European Regulatory Perspective
    Carleer, Jacqueline
    Karres, Janina
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2011, 92 (04) : 254 - 260
  • [3] Value of Juvenile Animal Studies
    Leconte, Isabelle
    Bailey, Graham
    Davis-Bruno, Karen
    Hew, Kok Wah
    Kim, James
    Lima, Beatriz Silva
    Liminga, Ulla
    Moffit, Jeffrey
    De Schaepdrijver, Luc
    Schmitt, Georg
    Tassinari, Melissa
    Thompson, Kary
    Hurtt, Mark
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2011, 92 (04) : 292 - 303
  • [4] Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective
    van der Laan, Jan Willem
    van Malderen, Karen
    de Jager, Nico
    Duarte, Dinah
    Egger, Gunter F.
    Lavergne, Fabien
    Roque, Claudio Gouveia
    Vieira, Isabel
    Wiesner, Lutz
    Carleer, Jacqueline
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2019, 38 (06) : 456 - 475
  • [6] Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials
    Visalli, Thomas
    Bower, Nancy
    Kokate, Tushar
    Andrews, Paul A.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2018, 96 : 167 - 177
  • [7] Developing drugs for pediatric use: a role for juvenile animal studies?
    Baldrick, P
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2004, 39 (03) : 381 - 389
  • [8] Juvenile animal studies in pediatric drug development: What is the evidence?
    Zajicek, Anne
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (09) : 1272 - 1272
  • [9] The Value of Juvenile Animal Studies "What Have We Learned From Preclinical Juvenile Toxicity Studies? II"
    Bailey, Graham P.
    Marien, Dirk
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2011, 92 (04) : 273 - 291
  • [10] Neuropathology Evaluation in Juvenile Toxicity Studies in Rodents: Comparison of Developmental Neurotoxicity Studies for Chemicals With Juvenile Animal Studies for Pediatric Pharmaceuticals
    Bolon, Brad
    Dostal, Lori A.
    Garman, Robert H.
    TOXICOLOGIC PATHOLOGY, 2021, 49 (08) : 1405 - 1415